Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Department of Pediatrics, Ochsner Hospital for Children, Jefferson, LA.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):174-180. doi: 10.1182/hematology.2021000250.
The landscape of sickle cell disease (SCD) treatment continues to evolve rapidly, with new disease-modifying therapies in development and potentially curative options on the horizon. Until recently, allogeneic stem cell transplant has been the only proven cure for SCD. Gene therapy is rising to the forefront of the discussion as a potentially curative or highly disease- modifying option for abating the complications of the disease. Understanding the different types of gene therapy in use, the differences in their end points, and their potential risks and benefits will be key to optimizing the long-term use of this therapy.
镰状细胞病(SCD)的治疗领域正在迅速发展,新的疾病修饰疗法正在开发中,潜在的治愈方法也即将出现。直到最近,异基因造血干细胞移植一直是 SCD 唯一被证实的治愈方法。基因疗法作为一种潜在的治愈或高度疾病修饰方法,正在成为治疗疾病并发症的讨论热点。了解正在使用的不同类型的基因疗法、它们终点的差异以及它们的潜在风险和益处,将是优化这种疗法长期使用的关键。